Center for Surveillance, Epidemiology, and Laboratory Services



Overview of the Draft Lyme and Tickborne Rickettsial Diseases Message Mapping Guide (MMG)

Tony Winters, MSPH
Amy Schwartz, MPH
Kristen Nichols Heitman, MPH

September 6, 2018

Agenda

- Lyme and Tickborne Rickettsial Diseases (TBRD) background
- Message Mapping Guide (MMG) overview
- Example test messages and scenarios
- Objectives of external review
 - Key areas for feedback
 - Process for external review
- Questions or Comments

Background

Lyme Disease: Background

- Lyme disease: a nationally notifiable condition since 1991
 - 5th–6th most common of all notifiable conditions
 - Often 2nd or 3rd most common in high-incidence states
- CDC receives Lyme disease surveillance data from jurisdictions and tabulates annually to describe national trends
 - Disease-specific "extended record" contains clinical and laboratory fields in addition to core NNDSS variables
 - Content and format of extended record hasn't been updated to match current disease and informatics standards

Recent Summary of Lyme Disease Surveillance Data

- 208,834 confirmed & 66,755 probable cases reported during 2008–2015
- ~60% of confirmed case records contained indication of ≥1 clinical manifestation necessary for confirmed status
- 3% of probable records contained indication of confirmatory clinical manifestations, suggestive of data transmission issues
- While transmitted successfully for some records, others contain mixtures of letters, numbers, or symbols, but most fields are empty.


Tickborne Rickettsial Diseases (TBRD): background

- Rocky Mountain spotted fever (RMSF) has been nationally notifiable since the 1920s. In 2010, the category was changed to Spotted Fever Rickettsiosis (SFR) to capture cases caused by all spotted fever group Rickettsia.
- Ehrlichiosis became nationally notifiable in 1999. In 2008, ehrlichiosis case definition split into four categories:
 - Ehrlichia chaffeensis infection
 - Ehrlichia ewingii infection
 - Anaplasma phagocytophilum infection
 - Undetermined ehrlichiosis/anaplasmosis

TBRD Surveillance Data

- Nationally Notifiable Diseases Surveillance System (NNDSS)
 - Only basic demographic data are currently received
- Supplemental data are currently collected by jurisdictions using the one-page TBRD case report form (CRF)
 - Clinical, laboratory, and case outcome data
- Data used to report national trends and influence public health policy and practices

| Atlanta, Georgia 30333 Use for: Spotted fever rickettslosis (SFR) ind Enritchiosis (£. chaffeensis, E. evirgii, a undet.). Visit http://www.cdc.gov and use "Se | Al Disease Case Report thuting Rocky Mountain spotted freet (RMSF), and Anaplasmosis (A, fragory injoithum a undet.), ard fragistamosis (A, fragory injoithum a undet.), ard fragistamosis (A fragory injoithum a undet.), ard fragistamosis (A fragory injoithum a undet.), and a |
|--|--|
| name: Address: (number, street) | Submitted: Fig. Cape Ca |
| (61-62) (60-64) (65-66) (100-6 | American Inclain Asskan Native 5 Pacific Islander Asskan 9 Not specified 7. Hispanic 1 Yes ethnicity: 2 No (19 g Uek |
| 9. Was a clinically compatible liliness present? remain operand distribution for the latinous Clinical entitions. I new and one in more of the billioning rate primarily SFRI, headachs, impaigs, among luckoporials (SrinicA, Angelias, Distributiopins) (SrinicA, Angelias, Distributiopins) of which deposits branching including the same of the strong possible text bits present? 11. Was an underlying immunosuppressive condition present? and the same of the same | chaffeens/s+ Etrilichiosis - E. ewingii Undetermined 02) Undetermined 10. Date of Orset of Symptomise |
| 13. Was the patient hospitalized because of this liliness? (req. (if yes, date) 1 YES 2 NO 9 J/nk (re-49 poet) (mm/95/yyy) 15. Name of | Disseminated intravasoular coagulogathy (DIC) 4 Renal failure n None Diber: 14. Did the patient die because of this lilness? _(NF) (If yes, date) 1 NES 2 NO 0 Unk (SAME (SEAM) POTED (IRRADSYNN) |
| 16. Serologic Serologic Tests Serologic Tests Serologic Serolo | State: V Dp. 1. Lack of Selection Indicates that the test or procedure was not performed. 1. Tother Respositor Test? Positive? 1. Other Respositor Test? 2. Other Respositor Test? 3. Other Respositor Test? 4. Other Respositor Test? 4. Other Respositor Test? 4. Other Respositor Test? 4. Other Respositor Test? 5. Other Respositor Test? 5. Other Respositor Test? 5. Other Respositor Test? 5. Other Respositor Test? 6. Other Respositor Test? 7. Other Respositor Test? 7. Other Respositor Test? 7. Other Respositor Test? 8. Other Respositor Test? 9. Other Respositor Test? 1. Other Respositor Test? 1. Other Respositor Te |
| | |
| 18. Classify case BASED ON the CDC case definition (see criteria below): | State Health Department Official who reviewed this report: Name: Doile: |
| SFR (Including (MSF) | Name: Title: Date: Confirmed Etritichiosis/Anaplasmosis: A circular competitive case with evidence of a burded visual part of the confirmed confirmed the confirmed |




Why Implement the Lyme and Tickborne Rickettsial Diseases MMG?

- Will make complete data available to CDC programs much sooner to help identify increases in frequency and geographic expansion of diseases
- Extensive time and resources are devoted to capturing clinical details and laboratory test information; yet, limitations in data transmission hinder ability to use data to influence public health policy and recommendations at CDC
- Opportunity to improve data transmission and consolidate data streams to reduce burden on jurisdictions in reporting cases
- MMGs allow jurisdictions to map variables that CDC can receive and compile electronically
- Lead to the retirement of the TBRD paper case report form

MMG Overview

MMG Overview

- Updates the current message being used to facilitate Lyme disease data transmission
- Allows for TBRD-specific data elements to be transmitted electronically to CDC for the first time
- Allows data elements to be sent using HL7 messaging



MMG Overview

| Α | В | С | D | | | E | F | G | Н |
|-------------------------------------|---|-------------------|--|---|---|--------------|-----------------|---------------------|------------------------------------|
| Data Element (DE) Name | DE Identifier Sent in HL7 Message | DE Code System | Data | a Element De | escription | Data Type | CDC Priority | May Repeat | Value Set Name (VADS Hyperlink) |
| Message Profile Identifier | N/A: MSH-21 | N/A | literal val in MSH-2 contain a notificati "PHINPr reference | e Profile Identi ue to use for t 21. MSH-21 v a reference to on type in the ofileID" names e to the impler eneric MMG in | he references vill always the pace and a nented version | Text | R | Y/3 | N/A |
| START: EPIDEMIOLOGIC | INFORMATION SE | CTION: The obser | vations in | this section | will be mappe | ed under | an "Epide | emiologic | Information" category |
| Exposure in high incidence state | INV1264 | PHINQUESTION | defined a | nt live in or vis as high incider or to onset of s | ice within 30 | Coded | Р | N | Yes No Unknown (YNU |
| Symptom onset greater than 30 days | INV1263 | PHINQUESTION | | | Coded | Р | N | Yes No Unknown (YNU | |
| START:Clinical Manifes | tations Repeating | Group | | | | | | | |
| Clinical Manifestation | INV930 | PHINQUESTION | Clinical i | manifestation (| of Lyme | Coded | P | N | Clinical Manifestations (Lyme) |
| Clinical Manifestation Indicator | 81265-1 | LN | | clinical manif | | Coded | Р | N | Yes No Unknown (YNU |
| ∢ → Introducti | on MMG Colu | mn Descriptions | Lyme | Lyme TS | Tickborne R | ickettsial [| Diseases | T.Ric | kettsial Diseases TS |

MMG Overview: Lyme Disease Data Elements Layout

- Lyme data elements tab includes 4 groups
 - Clinical Manifestation
 - Antibiotics/Treatment
 - Occupation and Industry
 - Epidemiology Laboratory Repeating Group

MMG Overview: TBRD Data Elements Layout

- TBRD data elements tab includes 7 groups
 - Physician Name/Number
 - Clinical Manifestation
 - Antibiotics/Treatment
 - Occupation and Industry
 - Epidemiology Laboratory Repeating Group
 - Travel History
 - Tick Bite

MMG Overview: Laboratory Template

- Laboratory template is not included in the MMG
- Laboratory template is optional for the tickborne MMG and can be found on the NNDSS website at

https://wwwn.cdc.gov/nndss/casenotification/related-documentation.html

 Click on the "MMG Related Documentation" section of the HL7 Case Notification Resource Center

MMG Related Documentation







This section contains documentation related to creating and sending case notification messages from public health entities to CDC for the new MMGs developed as part of NMI.

| Document | Notes |
|---|--|
| PHIN Messaging Specification for Case Notification v3.0 (Release 2-2: 4/1/2018) | This document has been updated to accommodate sending the Generic and disease-specific Message Mapping Guides (e.g., hepatitis, sexually transmitted diseases, congenital syphilis, pertussis, and mumps) and should be used with all new MMGs beginning in 2015 |
| Laboratory Template (Release 1; 5/11/2018) | his document includes the data elements for the "Laboratory Repeating Group" in the Message Mapping Guides. |
| Generic Data Elements that Define a Unique Case (Release 2; 7/7/2017) | Information for NNDSS reporting jurisdictions about which data elements in the Generic v2.0 MMG cannot change for a case because they are used to define a unique case in the CDC MVPS for HL7 case notifications |

How will Lyme Disease Data Elements Differ After This MMG is Implemented?

New data elements

- Exposure question (e.g. exposure in high incidence state)
- Symptom onset question (if symptoms began more than 30 days prior to specimen collection date)

Addition of valid values

 Valid values were added to improve data transmission (e.g. antibiotics, clinical signs and symptoms, laboratory variables)

How Will TBRD Data Elements Differ After this MMG is Implemented?

New data elements

- Clinical manifestations broken into symptoms
- Exposure history
- Treatment information
- Questions about history of blood transfusions/donations and organ transplants
- Co-infection diagnosis

Addition of valid values

 Valid values were added to improve data transmission (e.g. antibiotics, clinical signs and symptoms, laboratory variables)

Example Test Scenarios:

Sample Test Scenarios and Messages

- Test Scenario in the MMG
- Test Messages
 - https://wwwn.cdc.gov/nnds s/casenotification/messagemapping-guides.html, click "MMGs in Development"

| Data Element (DE) Name | DE Identifier Sent in HL7 Message | DE Code System | Data Ele | ment Description | Test Case 01 Description: Sample valid values for 25-year old, | | |
|-------------------------------|---|-------------------|--|---|---|--|--|
| | | | | | Hispanic or Latino, male, hospitalized, laboratory-reported notifiable non-outbreak associated condition, recovered, confirmed case, non-travel associated, Lyme Disease (Condition Code – 11080) | | |
| Message Profile Identifier | N/A: MSH-21 | N/A | literal value to references in always conta notification ty "PHINProfileII reference to t | use for the MSH-21. MSH-21 will in a reference to the | a NOTF_ORU_v3.0^PHINProfil eID^2.16.840.1.114222.4.10.3 ^ISO | | |
| Subject Related | | | | | | | |
| Local Subject ID | N/A: PID-3 | N/A | The local ID of the subject/entity | | TickborneLyme_Case01 | | |
| Birth Date | N/A: PID-7 | N/A | Patient's date of birth | | 19930601 | | |
| Subject's Sex | N/A: PID-8 | N/A | Subject's current sex | | M=Male | | |
| Race Category | N/A: PID-10 | N/A | Categories. E information w | ategory - Major OMB Race viries. Detailed race ation would be rolled up to najor OMB race categories. | | | |
| Introduction | MMG Column D | escriptions Lyme | Lyme TS | Tickborne Rickettsial D | iseases T.Rickettsial Disease | | |

Objectives of the External Review and Timeline

External Review Objectives

- Identify discrepancies in the message mapping guide
 - Are value sets adequate?
- Identify areas for technical clarification
 - Are there unclear data elements?
 - Do you know which data elements to send for each condition?
- Assess feasibility of IT implementation in your state
 - Which variables will not easily map to the MMG?
 - Is your state able to send both formats of lab data (lab template and lab data elements) within condition-specific tabs?

Lyme and Tickborne Rickettsial Diseases MMG Timeline

- 08/24/2018: External review for draft MMG began
- 09/6/2018: Webinar to present draft MMG for feedback
- 09/21/2018: External review for draft MMG closes
- Late September: MMG team with Lyme and TBRD epidemiologist will review feedback and update MMG
- Early October: Pilot Test-Ready Lyme and Tickborne Rickettsial Diseases
 MMG

How to Submit Feedback

- Please provide feedback by Friday, September 21st
- To report your feedback, please use the Lyme and Tickborne Rickettsial
 Diseases MMG feedback document: https://wwwn.cdc.gov/nndss/case-notification/message-mapping-guides.html, click "MMGs in Development" tab
- Email feedback to: edx@cdc.gov
- Subject line: "Draft Lyme and TBRD MMG Feedback"
- Feedback will be reviewed by CDC; outcome of reconciliation available
 - To submit a request for reconciled feedback, please contact edx@cdc.gov, subject line "Request for Lyme and TBRD Reconciled Feedback"

Questions?

For more information, contact CDC 1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

